Matthew C. Kapusta Sells 21,690 Shares of Uniqure NV (QURE) Stock

Uniqure NV (NASDAQ:QURE) CEO Matthew C. Kapusta sold 21,690 shares of Uniqure stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $19.87, for a total value of $430,980.30. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Uniqure NV (NASDAQ QURE) traded down $0.43 during midday trading on Friday, hitting $19.48. The stock had a trading volume of 254,785 shares, compared to its average volume of 418,871. Uniqure NV has a 12-month low of $4.72 and a 12-month high of $21.35. The stock has a market cap of $598.69, a P/E ratio of -7.46 and a beta of 0.72. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC boosted its stake in shares of Uniqure by 4.1% in the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock worth $9,656,000 after buying an additional 61,650 shares during the last quarter. Mangrove Partners boosted its stake in shares of Uniqure by 167.4% in the 3rd quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock worth $1,024,000 after buying an additional 66,763 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Uniqure by 33.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after buying an additional 14,659 shares during the last quarter. Finally, OxFORD Asset Management LLP purchased a new position in shares of Uniqure in the 3rd quarter worth approximately $399,000. Hedge funds and other institutional investors own 24.87% of the company’s stock.

A number of research firms have issued reports on QURE. ValuEngine upgraded Uniqure from a “sell” rating to a “hold” rating in a research note on Monday. Janney Montgomery Scott began coverage on Uniqure in a research note on Wednesday. They set a “buy” rating and a $25.00 price target for the company. BidaskClub upgraded Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. HC Wainwright began coverage on Uniqure in a research note on Friday, December 1st. They set a “buy” rating and a $28.00 price target for the company. Finally, Oppenheimer reiterated a “hold” rating on shares of Uniqure in a research note on Friday, November 24th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $20.00.

WARNING: “Matthew C. Kapusta Sells 21,690 Shares of Uniqure NV (QURE) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/05/matthew-c-kapusta-sells-21690-shares-of-uniqure-nv-qure-stock.html.

Uniqure Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply